accelerated approval

During my years as an FDA official, I learned that there is a fundamental fact of life that underlies all drug testing and regulatory review: The data are seldom as complete and unequivocal as you might like.

Recently the U.S. Food and Drug Administration granted accelerated approval to aducanumab (Aduhelm), the first Alzheimer’s Disease treatment since 2003.